Geron Corporation (0IV3.L)

USD 1.3

(-12.19%)

Long Term Debt Summary of Geron Corporation

  • Geron Corporation's latest annual long term debt in 2023 was 35.05 Million USD , up 3.45% from previous year.
  • Geron Corporation's latest quarterly long term debt in 2024 Q2 was 36.51 Million USD , up 225.51% from previous quarter.
  • Geron Corporation reported annual long term debt of 33.88 Million USD in 2022, down -37.37% from previous year.
  • Geron Corporation reported annual long term debt of 54.09 Million USD in 2021, up 87.57% from previous year.
  • Geron Corporation reported quarterly long term debt of 36.51 Million USD for 2024 Q2, up 225.51% from previous quarter.
  • Geron Corporation reported quarterly long term debt of 54.91 Million USD for 2023 Q1, up 62.06% from previous quarter.

Annual Long Term Debt Chart of Geron Corporation (2023 - 1996)

Historical Annual Long Term Debt of Geron Corporation (2023 - 1996)

Year Long Term Debt Long Term Debt Growth
2023 35.05 Million USD 3.45%
2022 33.88 Million USD -37.37%
2021 54.09 Million USD 87.57%
2020 28.84 Million USD 1210.95%
2019 2.2 Million USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%
2010 - USD 0.0%
2009 - USD 0.0%
2008 - USD 0.0%
2007 - USD 0.0%
2006 - USD 0.0%
2005 - USD -100.0%
2004 645 Thousand USD -43.96%
2003 1.15 Million USD -94.39%
2002 20.51 Million USD 23.63%
2001 16.59 Million USD -48.84%
2000 32.43 Million USD 89.68%
1999 17.1 Million USD 111.11%
1998 8.1 Million USD 523.08%
1997 1.3 Million USD -18.75%
1996 1.6 Million USD 0.0%

Peer Long Term Debt Comparison of Geron Corporation

Name Long Term Debt Long Term Debt Difference
uniQure N.V. 130.06 Million USD 73.051%
Agios Pharmaceuticals, Inc. 56.98 Million USD 38.494%
Amicus Therapeutics, Inc. 387.85 Million USD 90.963%
Atara Biotherapeutics, Inc. 45.69 Million USD 23.29%
bluebird bio, Inc. 224.41 Million USD 84.381%
Cara Therapeutics, Inc. 37.07 Million USD 5.469%
Imunon, Inc. 1.13 Million USD -2976.557%
Editas Medicine, Inc. 24.37 Million USD -43.817%
IQVIA Holdings Inc. 12.95 Billion USD 99.729%
Mettler-Toledo International Inc. 1.97 Billion USD 98.226%
Myriad Genetics, Inc. 130.9 Million USD 73.223%
Neurocrine Biosciences, Inc. 258.3 Million USD 86.43%
Supernus Pharmaceuticals, Inc. 33.19 Million USD -5.588%
Verastem, Inc. 40.08 Million USD 12.56%
Walgreens Boots Alliance, Inc. 8.04 Billion USD 99.564%
Waters Corporation 2.3 Billion USD 98.48%
Thermo Fisher Scientific Inc. 31.3 Billion USD 99.888%
Biogen Inc. 7.18 Billion USD 99.512%
Nektar Therapeutics 112.62 Million USD 68.878%
Perrigo Company plc 3.63 Billion USD 99.035%
Dynavax Technologies Corporation 252.41 Million USD 86.114%
Illumina, Inc. 1.48 Billion USD 97.646%
Corbus Pharmaceuticals Holdings, Inc. 3.23 Million USD -982.278%
Iovance Biotherapeutics, Inc. 1 Million USD -3405.1%
Heron Therapeutics, Inc. 173.75 Million USD 79.827%
Unity Biotechnology, Inc. 23.53 Million USD -48.906%
BioMarin Pharmaceutical Inc. 593.09 Million USD 94.09%
Sangamo Therapeutics, Inc. 33.51 Million USD -4.583%
Evolus, Inc. 120.35 Million USD 70.878%
Adicet Bio, Inc. 17.7 Million USD -97.995%
Aclaris Therapeutics, Inc. 3.07 Million USD -1040.241%
Regeneron Pharmaceuticals, Inc. 2.7 Billion USD 98.703%
Esperion Therapeutics, Inc. 501.54 Million USD 93.011%
FibroGen, Inc. 89.69 Million USD 60.923%
Agilent Technologies, Inc. 2.73 Billion USD 98.718%
OPKO Health, Inc. 222.03 Million USD 84.214%
Homology Medicines, Inc. 43.17 Million USD 18.818%
Alnylam Pharmaceuticals, Inc. 2.34 Billion USD 98.504%
Exelixis, Inc. 189.94 Million USD 81.547%
Viking Therapeutics, Inc. 936 Thousand USD -3644.765%
Anavex Life Sciences Corp. - USD -Infinity%
Intellia Therapeutics, Inc. 96.74 Million USD 63.77%
Zoetis Inc. 6.56 Billion USD 99.466%
Axsome Therapeutics, Inc. 178.07 Million USD 80.316%
Abeona Therapeutics Inc. 4.4 Million USD -696.252%
Vertex Pharmaceuticals Incorporated 724.7 Million USD 95.163%
Kala Pharmaceuticals, Inc. 34.19 Million USD -2.518%
Ionis Pharmaceuticals, Inc. 1.4 Billion USD 97.497%
Sarepta Therapeutics, Inc. 1.13 Billion USD 96.905%
Corcept Therapeutics Incorporated - USD -Infinity%
Halozyme Therapeutics, Inc. 1.49 Billion USD 97.662%
Blueprint Medicines Corporation 610.96 Million USD 94.263%
Insmed Incorporated 1.19 Billion USD 97.063%
TG Therapeutics, Inc. 100.11 Million USD 64.99%
Incyte Corporation 29.16 Million USD -20.194%
Emergent BioSolutions Inc. 446.5 Million USD 92.15%